Friday, 28 February 2014

Cardiovascular Risk Profile in Subjects With Prediabetes and New-Onset Type 2 Diabetes Identified by HbA1c 

These data suggest that a simple, reproducible, and less expensive marker such as HbA1c may be better able to identify prediabetic subjects at high cardiovascular risk compared with fasting glycemia or OGTT alone (Diabetes Care)

Janssen announce the launch of INVOKANA® (canagliflozin) in the UK

UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes1 - press release (Janssen)

Thursday, 27 February 2014

Many faces of monogenic diabetes

Patients with neonatal diabetes require a thorough genetic work-up in any case, and because extensive phenotypic overlap exists between monogenic, type 2, and type 1 diabetes, genetic analysis will also help improve diagnosis in these cases (Journal of Diabetes Investigation)


Nitric oxide system and diabetic nephropathy

Nitric oxide synthase (NOS) seems to be involve in the development and progression of Diabetic nephropathy (DN). Despite the discrepant results of many studies, the eNOS gene is also a good candidate gene for DN (Diabetology & Metabolic Syndrome)

Wednesday, 26 February 2014

Urinary Methylmalonic Acid as an Indicator of Early Vitamin B12 Deficiency and Its Role in Polyneuropathy in Type 2 Diabetes

Urinary methylmalonic acid correlates with serum vitamin B12 levels in person with diabetes and is a sensitive marker of early polyneuropathy (Journal of Diabetes Research)


National Paediatric Diabetes Audit

Part 2: hospital admissions and complications (Healthcare Quality Improvement Partnership)



Tuesday, 25 February 2014

Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes

In the AWARD-6 study, once-weekly dulaglutide 1.5 mg achieved the primary endpoint of non-inferiority to once-daily liraglutide 1.8 mg, as measured by the reduction of hemoglobin A1c (HbA1c) from baseline at 26 weeks (Lilly)

Monday, 24 February 2014

Janssen announce the launch of INVOKANA® (canagliflozin) in the UK

UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes1 - press release (Janssen)

Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients

Reduction in UAE is associated with reduced risk of MI and stroke in diabetic and/or hypertensive patients. These findings suggest that UAE changes may represent a valuable intermediate end-point for CV risk evaluation in clinical practice (International Journal of Cardiology)

Sunday, 23 February 2014

Type 2 diabetes in Australia's children and young people: a working paper

This working paper also presents, for the first time, national incidence and prevalence estimates of type 2 diabetes in Australia's children and young people (AIHW)

Saturday, 22 February 2014

A type I interferon transcriptional signature precedes autoimmunity in children genetically at-risk of type 1 diabetes

These findings identify transient increased expression of type I IFN genes in pre-clinical diabetes as a risk factor for autoimmunity in children with a genetic predisposition to T1D (Diabetes)

Friday, 21 February 2014

Pathways to diagnosis: a qualitative study of the experiences and emotional reactions of parents of children diagnosed with type 1 diabetes

Parents' and other people's knowledge about T1D can affect the duration between onset of their child's symptoms and diagnosis. Campaigns to raise awareness should ensure that parents are made aware of symptoms and that T1D can develop during childhood. (Pediatric Diabetes)


Glycemic Variability in Patients With Early Type 2 Diabetes: The Impact of Improvement in ß-Cell Function

In early T2DM, glycemic variability is a modifiable parameter that can be reduced by improving ß-cell function with short-term intensive insulin therapy (Diabetes Care)

Wednesday, 19 February 2014

GLP-1 receptor agonists

Why is once weekly inferior to once daily? (The Lancet Diabetes & Endocrinology)

Improving outcomes for patients with type 2 diabetes using general practice networks: a quality improvement project in east London

Investment of financial, organisational and education resources into primary care practice networks can achieve clinically important improvements in diabetes care in deprived, ethnically diverse communities (BMJ Quality and Safety)

Gestational diabetes induces alterations in the function of neonatal endothelial colony-forming cells

Intrauterine exposure of endothelial colony-forming cells (ECFCs) to GDM induces unique phenotypic alterations. The resistance of GDM-exposed ECFCs to hyperglycemia-induced senescence and decreased p38MAPK activation suggest that these progenitor cells have undergone changes that induce tolerance to a hyperglycemic environment (Pediatric Research)


Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

In this Review, we explore the overlapping pathophysiology and also how various treatments can, alone or in combination, combat the dual burden of obesity and type 2 diabetes (The Lancet Diabetes & Endocrinology)


Together for Health – A Diabetes Delivery Plan

A Delivery Plan up to 2016 for NHS Wales and its partners (Welsh Government)


Commissioning and funding general practice

Making the case for family care networks (King's Fund)

Tuesday, 18 February 2014

Does higher quality of primary healthcare reduce hospital admissions for diabetes complications? A national observational study

After controlling for population factors, better scheduled primary care access and glycaemic control were associated with lower hospital admission rates across most complications (Diabetic Medicine)


Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006–2008

Approximately one third of the study population had no record of statin prescription during the 2 years after diagnosis of diabetes. Cardiovascular disease risk reduction opportunities may be missed in some of these people (Diabetic Medicine)

Monday, 17 February 2014

Why sponsor Glycosmedia?
Postprandial C-peptide to glucose ratio as a predictor of ß-cell function and its usefulness for staged management of type 2 diabetes

We suggest that PCGR might be a useful marker for ß-cell function and an ancillary parameter in the choice of antidiabetic medication in type 2 diabetes (Journal of Diabetes Investigation)


Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria

A definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated (Diabetes Research and Clinical Practice)


Psychological Care in a National Health Service: Challenges for People with Diabetes

This review highlights the barriers and challenges to optimizing care for patients with co-morbid diabetes and depression, and outlines the therapies currently available in the UK, which might be disseminated in other countries (Current Diabetes Reports)



Friday, 14 February 2014

Lixisenatide Resensitizes The Insulin-Secretory Response To Intravenous Glucose Challenge In People With Type 2 Diabetes – A Study In Both People With Type 2 Diabetes And Healthy Subjects

Lixisenatide thereby accelerates glucose disposal to nearly physiological intensity, and does not impair counter-regulation to low glucose levels by glucagon (Diabetes, Obesity and Metabolism)

Wednesday, 12 February 2014

Initial Management of Severe Hyperglycemia in Patients with Type 2 Diabetes: an Observational Study

Insulin therapy was used in roughly two-thirds of patients with severe hyperglycemia, but did not result in better glycemic control compared to non-insulin regimens (Diabetes Therapy)

Tuesday, 11 February 2014

Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision

Egeneron Pharmaceuticals and Bayer HealthCare announced that in the Phase 3 VISTA-DME trial of EYLEA® (aflibercept) injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections0 showed a sustained improvement from baseline in best corrected visual acuity at week 100, compared to laser photocoagulation (Egeneron)

Elevation of plasma advanced oxidation protein products is an early marker of endothelial dysfunction in type 2 diabetes patients without albuminuria

Elevation of plasma advanced oxidized protein products was an independent risk factor for endothelial dysfunction, and therefore, might be an early marker of vasculopathy in individuals with early stage of diabetes (Journal of Diabetes)


Autoimmune Aspects of Type 2 Diabetes Mellitus - A Mini-Review

The identification of autoantibodies in elderly patients with slowly progressive manifestation of diabetes led to the introduction of a distinct clinical entity termed latent autoimmune diabetes of the adult (LADA), which combines features of both T1DM and T2DM (Gerontology)


Structural and Functional Brain Changes in Middle-Aged Type 2 Diabetic Patients: A Cross-Sectional Study

In agreement with previous reports, our findings indicate that T2DM leads to structural and metabolic abnormalities in fronto-temporal areas. Furthermore, they suggest that these abnormalities are not entirely explained by the role of T2DM as a cardiovascular risk factor (Journal of Alzheimer's Disease)

Monday, 10 February 2014

Number of people diagnosed with diabetes reaches 3.2 million

The new figures, extracted from official NHS data, show that there were 3,208,014 adults with the condition in 2013, an increase of more than 163,000 compared to 2012 (Diabetes UK)


Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes

MSD and Samsung Bioepis announce that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon (Merck)


A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus

BIAsp 30 added to OAD therapy results in a better glycaemic control as compared with IGlar in T2DM patients. BIAsp 30 use is associated with slightly larger weight gain but no rise in risk of severe hypoglycaemic episodes (International Journal of Clinical Practice)


High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women

High E2 level is an independent predictor of incident dementia, particularly in postmenopausal women with diabetes (Neurology)


GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

GLP-1RAs provide superior glycaemic control and weight loss vs. DPP-4 inhibitors in patients with T2D. DPP-4 inhibitors may sometimes be preferred to a GLP-1RA if weight is not a concern, oral administration is a desirable feature or when a GLP-1RA cannot be tolerated (International Journal of Clinical Practice)

Friday, 7 February 2014

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Our findings may therefore provide a useful approach for generating large numbers of functional ß cells for disease modeling and, ultimately, cell-based therapy (Cell)

Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease

Our study demonstrates that patients with type 2 diabetes have higher circulating levels of cyclophilin A than the normal population. Plasma cyclophilin levels were increased in patients with diabetes and coronary artery disease suggesting a role of this protein in accelerating vascular disease in type 2 diabetes (Cardiovascular Diabetology)


Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy

These data support the use of insulin pumps in this youngest age group, and suggest that metabolic control may be improved without increasing the frequency of severe hypoglycemia, but care should be taken as to the possibly increased risk of DKA (Pediatric Diabetes)

Wednesday, 5 February 2014

Dopamine Deficiency Contributes to Early Visual Dysfunction in a Rodent Model of Type 1 Diabetes

Our results indicate that retinal Dopamine deficiency is an underlying mechanism for early, diabetes-induced visual dysfunction and suggest that therapies targeting the retinal dopaminergic system may be beneficial in early-stage DR (Journal of Neuroscience)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus

It is possible to achieve similar glycemic control with once-daily injection and lower doses of insulin degludec in patients with T1DM who have been treated with insulin glargine or detemir (Diabetes Therapy)


Use of clinical targets in diabetes patient education: qualitative analysis of the expectations and impact of a structured self-management programme in Type 1 diabetes

Specific and measurable low HbA1c targets may be desirable for reducing the risk of complications in diabetes, but they are not attainable or realistic even for most graduates from the Dose Adjustment for Normal Eating programme. It is suggested that setting goals without information about how achievable they really are could be counterproductive in terms of supporting and maintaining patient self-efficacy long-term (Diabetic Medicine)

Tuesday, 4 February 2014

Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels

In participants with long-standing T2DM and at high risk for cardiovascular events, intensive BP control and fibrate therapy in the presence of controlled low-density lipoprotein cholesterol levels did not produce a measurable effect on cognitive decline at 40 months of follow-up. Intensive BP control was associated with lower decline in TBV at 40 months relative to standard therapy (JAMA Internal Medicine)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Analysis of pooled data from 20 clinical trials in patients with T2DM suggests that saxagliptin is not associated with an increased CV risk (Cardiovascular Diabetology)


Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia

In patients with diabetes and CLI mortality after two years is high. Life expectancy was better in patients receiving combined therapy with ACE and statin but not with therapy with only a statin or an ACE (Diabetes Research and Clinical Practice)


Stepping up: a nurse-led model of care for insulin initiation for people with type 2 diabetes

The Stepping Up model allowed technical care to be embedded within generalist whole-person care, supported clinicians and practice system to overcome clinical inertia and supported patients to make the timely transition to insulin (Family Practice)


Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus

Future models should aim to include all relevant treatment outcomes, whether these relate to effects on underlying diabetes and its complications or to short- or long-term side effects of treatment. We need to explore why cost-saving interventions could benefit further from adding patient characteristics, which may be able to better predict the use of lower-cost alternatives (PharmacoEconomics)

Monday, 3 February 2014

Increases in insulin sensitivity among obese youth are associated with gene expression changes in whole blood

Participants that increased insulin sensitivity exhibited five times the number of significant genes altered compared to non-responders (Obesity)


Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin

Once-daily lixisenatide significantly improved glycemic control, with a pronounced postprandial effect, without significant increase in symptomatic/severe hypoglycemia risk and with weight loss over 24 weeks (Diabetes and Its Complications)


Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years’ duration

Even after long duration of diabetes, addition of glimepiride to insulin and metformin can be effective in lowering HbA1c and/or reducing the need for exogenous insulin (Diabetes Research and Clinical Practice)


AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance

AstraZeneca announce that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance (AstraZeneca)